Clinical Policy: Epoetin alfa (Epogen, Procrit), Epoetin alfa-epbx (Retacrit)
Reference Number: CP.CPA.321
Effective Date: 06.01.18
Last Review Date: 05.19
Line of Business: Commercial

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
The following are erythropoiesis-stimulating agents (ESA) requiring prior authorization: epoetin alfa (Epogen® and Procrit®) and epoetin alfa-epbx (Retacrit™).

FDA Approved Indication(s)
Epogen, Procrit, and Retacrit are indicated for:

- Treatment of anemia due to:
  - Chronic kidney disease (CKD) in patients on dialysis and not on dialysis.
  - Zidovudine in patients with HIV-infection.
  - The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
- Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery.

Limitation(s) of use:
- Epogen, Procrit, and Retacrit have not been shown to improve quality of life, fatigue, or patient well-being.
- Epogen Procrit, and Retacrit are not indicated for use:
  - In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy.
  - In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
  - In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion.
  - In patients scheduled for surgery who are willing to donate autologous blood.
  - In patients undergoing cardiac or vascular surgery.
  - As a substitute for RBC transfusions in patients who require immediate correction of anemia.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Epogen, Procrit, and Retacrit are medically necessary when the following criteria are met:
I. Initial Approval Criteria

A. Anemia due to Chronic Kidney Disease (must meet all):
   1. Diagnosis of anemia of CKD (dialysis and non-dialysis members);
   2. Prescribed by or in consultation with a hematologist or nephrologist;
   3. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%;
   4. Pretreatment hemoglobin level < 10 g/dL;
   5. If Epogen or Retacrit is requested, failure of Procrit unless contraindicated or clinically significant adverse effects are experienced.
   Approval duration: 6 months or to member’s renewal period, whichever is longer

B. Anemia due to Zidovudine in HIV-infected Patients (must meet all):
   1. Diagnosis of zidovudine induced anemia;
   2. Prescribed by or in consultation with a hematologist or HIV specialist;
   3. Member is HIV-positive;
   4. Dose of zidovudine is ≤ 4,200 mg/week;
   5. Endogenous serum erythropoietin levels ≤ 500 mUnits/mL;
   6. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%;
   7. Pretreatment hemoglobin level < 10 g/dL;
   8. If Epogen or Retacrit is requested, failure of Procrit unless contraindicated or clinically significant adverse effects are experienced.
   Approval duration: 6 months or to member’s renewal period, whichever is longer

C. Anemia due to Chemotherapy in Patients with Cancer (must meet all):
   1. Diagnosis of anemia due to chemotherapy;
   2. Prescribed by or in consultation with a hematologist or oncologist;
   3. Age ≥ 5 years;
   4. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%;
   5. Pretreatment hemoglobin < 10 g/dL;
   6. If Epogen or Retacrit is requested, failure of Procrit unless contraindicated or clinically significant adverse effects are experienced.
   Approval duration: Until the completion of chemotherapy course, 6 months, or to member’s renewal date, whichever is longer

D. Reduction of Allogeneic Red Blood Cell Transfusions in Patients Undergoing Elective, Noncardiac, Nonvascular Surgery (must meet all):
   1. Member is at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery;
   2. Perioperative hemoglobin > 10 to ≤ 13 g/dL;
   3. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%;
   4. Member is unwilling or unable to donate autologous blood pre-operatively;

Page 2 of 9
5. If Epogen or Retacrit is requested, failure of Procrit unless contraindicated or clinically significant adverse effects are experienced.

Approval Duration: 15 days (for 300 Units/kg daily) OR 21 days (for 600 Units/kg in 4 doses)

E. Anemia Associated with Myelodysplastic Syndromes (off-label) (must meet all):
1. Diagnosis of anemia from myelodysplastic syndrome (MDS);
2. Prescribed by or in consultation with a hematologist or oncologist;
3. Age ≥ 18 years;
4. Current (within the last 3 months) serum erythropoietin (EPO) ≤ 500 mU/mL;
5. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%;
6. Pretreatment hemoglobin < 10 g/dL;
7. If Epogen or Retacrit is requested, failure of Procrit unless contraindicated or clinically significant adverse effects are experienced.

Approval duration: 6 months or to member’s renewal period, whichever is longer

F. Myelofibrosis-Associated Anemia (off-label) (must meet all):
1. Diagnosis of anemia associated with myelofibrosis;
2. Prescribed by or in consultation with a hematologist or oncologist;
3. Age ≥ 18 years;
4. Current (within the last 3 months) serum EPO < 500 mU/mL;
5. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%;
6. If Epogen or Retacrit is requested, failure of Procrit unless contraindicated or clinically significant adverse effects are experienced.

Approval duration: 6 months or to member’s renewal period, whichever is longer

G. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial.

II. Continued Therapy
A. Anemia due to Chronic Kidney Disease (must meet all):
1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation ≥ 20%.

Approval duration: 6 months or to the member’s renewal date, whichever is longer

B. Anemia due to Zidovudine in HIV-infected Patients (must meet all):
1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Current hemoglobin level is ≤ 12 g/dL;
3. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level $\geq 100$ mcg/L or serum transferrin saturation $\geq 20\%$.

**Approval duration:** 6 months or to the member’s renewal date, whichever is longer

**C. Anemia due to Chemotherapy in Patients with Cancer** (must meet all):
1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
2. Continuation of ESA therapy is concurrent with myelosuppressive chemotherapy;
3. If member has received $\geq 8$ weeks of ESA therapy, member meets both of the following (a and b):
   a. Documented evidence of response to therapy as evidenced by rise in hemoglobin levels $> 1$ g/dL;
   b. No RBC transfusions are required;
4. Current hemoglobin $< 10$ g/dL;
5. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level $\geq 100$ mcg/L or serum transferrin saturation $\geq 20\%$.

**Approval duration:** Until the completion of chemotherapy course, 6 months, or to member’s renewal date, whichever is longer

**D. Reduction of Allogeneic Red Blood Cell Transfusions in Patients Undergoing Elective, Noncardiac, Nonvascular Surgery**
1. Re-authorization is not permitted. Members must meet the initial approval criteria.

**Approval duration:** Not applicable

**E. Anemia Associated with Myelodysplastic Syndrome (off-label)** (must meet all):
1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
2. Member is responding positively to therapy;
3. Current hemoglobin $\leq 12$ g/dL;
4. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level $\geq 100$ mcg/L or serum transferrin saturation $\geq 20\%$.

**Approval Duration:** 6 months or to the member’s renewal date, whichever is longer

**F. Myelofibrosis-Associated Anemia (off-label)** (must meet all):
1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level $\geq 100$ mcg/L or serum transferrin saturation $\geq 20\%$.

**Approval duration:** 6 months or to the member’s renewal date, whichever is longer

**G. Other diagnoses/indications** (must meet 1 or 2):
1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

**Approval duration:** Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial.

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – CP.CPA.09 for commercial or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
CKD: chronic kidney disease
ESA: erythropoiesis-stimulating agent
FDA: Food and Drug Administration
HIV: human immunodeficiency virus
RBC: red blood cell

Appendix B: Therapeutic Alternatives
Not applicable

Appendix C: Contraindications/Boxed Warnings
• Contraindication(s):
  o Uncontrolled hypertension
  o Pure red cell aplasia (PRCA) that begins after treatment with erythropoietin protein drugs
  o Allergic reactions
  o Epogen/Procrit - Use of the multiple-dose vials containing benzyl alcohol in neonates, infants, pregnant women, and lactating women
• Boxed warning(s): ESAs increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access and tumor progression or recurrence

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anemia due to CKD</td>
<td>Initial dose: 50 to 100 units/kg 3 times weekly (adults) intravenously (IV) or subcutaneously (SC) and 50 units/kg 3 times weekly (children on dialysis) IV or SC. Individualize maintenance dose. IV route recommended for patients on hemodialysis</td>
<td>Varies depending on indication and frequency of administration</td>
</tr>
<tr>
<td>Anemia due to zidovudine in HIV-infected patients</td>
<td>100 units/kg IV or SC 3 times weekly</td>
<td></td>
</tr>
<tr>
<td>Anemia due to chemotherapy</td>
<td>40,000 units SC weekly or 150 units/kg SC 3 times weekly (adults) until completion of a chemotherapy course; 600 units/kg IV weekly (children ≥ 5 years)</td>
<td></td>
</tr>
<tr>
<td>Indication</td>
<td>Dosing Regimen</td>
<td>Maximum Dose</td>
</tr>
<tr>
<td>-----------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Reduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery</td>
<td>until completion of a chemotherapy course</td>
<td></td>
</tr>
<tr>
<td></td>
<td>300 units/kg per day SC daily for 15 days total: administered daily for 10 days before surgery, on the day of surgery, and for 4 days after surgery or 600 units/kg SC weekly in 4 doses administered 21, 14, and 7 days before surgery and on the day of surgery</td>
<td></td>
</tr>
<tr>
<td>Anemia associated with MDS†</td>
<td>40,000-60,000 units SC one to two times weekly</td>
<td></td>
</tr>
<tr>
<td>Anemia associated with myelofibrosis†</td>
<td>In a clinical trial, patients initially received erythropoietin 10,000 units SC 3 days per week. Erythropoietin was increased to 20,000 units 3 days per week if a response was not obtained after 2 months and erythropoietin was discontinued in patients who did not experience a response at 3 months.</td>
<td></td>
</tr>
</tbody>
</table>

† Off-label indication

VI. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epoetin alfa (Epogen)</td>
<td>• Single-dose vial: 2,000 units/mL, 3,000 units/mL, 4,000 units/mL, and 10,000 units/mL</td>
</tr>
<tr>
<td></td>
<td>• Multiple-dose vial containing benzyl alcohol: 20,000 units/2 mL and 20,000 units/mL</td>
</tr>
<tr>
<td>Epoetin alfa (Procrit)</td>
<td>• Single-dose vial: 2,000 units/mL, 3,000 units/mL, 4,000 units/mL, 10,000 units/mL, and 40,000 units/mL</td>
</tr>
<tr>
<td></td>
<td>• Multiple-dose vial containing benzyl alcohol: 20,000 units/2 mL and 20,000 units/mL</td>
</tr>
<tr>
<td>Epoetin alfa-epbx (Retacrit)</td>
<td>• Single-dose vial: 2,000 units/mL, 3,000 units/mL, 4,000 units/mL, 10,000 units/mL, 40,000 units/mL</td>
</tr>
</tbody>
</table>

VII. References


Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4081</td>
<td>Injection, epoetin alfa, 100 units (for ESRD on dialysis)</td>
</tr>
<tr>
<td>J0885</td>
<td>Injection, epoetin alfa, (for non-ESRD use), 1000 units</td>
</tr>
<tr>
<td>Q5105</td>
<td>Injection, epoetin alfa, biosimilar, (Retacrit) (for ESRD on dialysis), 100 units</td>
</tr>
<tr>
<td>Q5106</td>
<td>Injection, epoetin alfa, biosimilar, (Retacrit) (for non-ESRD use), 1000 units</td>
</tr>
</tbody>
</table>

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>01.12.18</td>
<td>05.18</td>
</tr>
</tbody>
</table>
Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>pretreatment hemoglobin levels; anemia due to chemotherapy: added age requirement as safety and effectiveness in pediatrics &lt; 5 years have not been established; added requirement for pretreatment hemoglobin level; reduction of RBC transfusion in surgery patients: added perioperative hemoglobin requirement per PI; anemia secondary to ribavirin/interferon alfa: added age and pretreatment hemoglobin requirements; anemia associated with MDS: added requirements related age, serum EPO and pretreatment hemoglobin levels; added NCCN compendial/recommended use (category 2A): MF-associated anemia; references reviewed and updated.</td>
<td></td>
<td>06.26.18 11.18</td>
</tr>
<tr>
<td>Added Retacrit to criteria; removed myelofibrosis-associated anemia, anemia due to myelodysplastic syndrome, anemia secondary to combination ribavirin and interferon-alfa therapy in patients infected with hepatitis C virus off label uses since DrugDex Ilb not covered; references reviewed and updated.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2Q 2019 annual review: added NCCN compendium supported uses for myelofibrosis-associated anemia and anemia due to myelodysplastic syndrome; references reviewed and updated</td>
<td>01.30.19</td>
<td>05.19</td>
</tr>
</tbody>
</table>

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a
discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions. Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.